Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Digoxin Dangers: A proportion of patients treated with digoxin, a cardiac glycoside used to treat heart function abnormalities, generate the inactive metabolite, dihydrodigoxin, resulting in poor efficacy. Haiser et al. (p. 295 ) examined a potential culprit responsible for this transformation—the actinobacterium, Eggerthella lenta —to probe the microbiota-digoxin interaction. Microbe growth was promoted by arginine, and differential expression analysis revealed a two-gene cardiac glycoside reductase ( cgr ) operon that was induced by digoxin in low arginine conditions. Not all strains of E. lenta could reduce digoxin and, when fecal samples from healthy people were tested, a spectrum of digoxin inactivation was detected. When the digoxin-reducing strain of E. lenta was given to germ-free mice that were fed a high-protein (that is, high-arginine) diet, digoxin levels stayed high in serum, and drug inactivation was suppressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Notably, the cgr ratio could be used to effectively discriminate microbial communities exhibiting low versus high digoxin reduction (Fig. 5).”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“The amino acid arginine prevents digoxin inactivation by E. lenta in vitro, decreasing the expression and activity of the genes responsible (the cgr operon)67.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“Because the intestine is a major site for drug metabolism (both by cytochrome P-450 enzymes in intestinal epithelial cells and by the gut microbiome87)”
From Microfluidic Organ-on-a-Chip Models of Human Intestine (2018) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Haiser et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“was inducible by the drug it metabolizes (Haiser et al., 2013).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Haiser et al., 2013
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer3—new capabilities and interfaces
Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B. C., Remm, M., & Rozen, S. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,461
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Versatile and open software for comparing large genomes
Kurtz, S., Phillippy, A., Delcher, A. L., Smoot, M., Shumway, M., Antonescu, C., & Salzberg, S. L. (2004) · Genome Biology · doi:10.1186/gb-2004-5-2-r12 · Cited by 5,254
Breitling, R., Armengaud, P., Amtmann, A., & Herzyk, P. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.055 · Cited by 1,496
Isolation of a Bacterium That Reductively Dechlorinates Tetrachloroethene to Ethene
Maymó-Gatell, X., Chien, Y.-T., Gossett, J. M., & Zinder, S. H. (1997) · Science · doi:10.1126/science.276.5318.1568 · Cited by 1,125
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
SSAHA: A Fast Search Method for Large DNA Databases
Ning, Z., Cox, A. J., & Mullikin, J. C. (2001) · Genome Research · doi:10.1101/gr.194201 · Cited by 965
Xenobiotics shape the physiology and gene expression of the active human gut microbiome
Maurice, C. F., Haiser, H. J., & Turnbaugh, P. J. (2013) · Cell · doi:10.1016/j.cell.2012.10.052 · Cited by 811
A Catalog of Reference Genomes from the Human Microbiome
The Human Microbiome Jumpstart Reference Strains Consortium, Nelson, K. E., Weinstock, G. M., Highlander, S. K., Worley, K. C., Creasy, H. H., Wortman, J. R., Rusch, D. B., Mitreva, M., Sodergren, E., et al. (2010) · Science · doi:10.1126/science.1183605 · Cited by 702
Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy
Lindenbaum, J., Rund, D. G., Butler, V. P., Tse-Eng, D., & Saha, J. R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110013051403 · Cited by 423
Cited by
Items 501–600 of 704
A suggestion for evolution of Canada’s health regulatory system
White, J., & Reid, G. (2018) · FACETS · doi:10.1139/facets-2017-0049 · Cited by 4
Diot, C., García-González, A. P., & Walhout, A. J. M. (2018) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2019.08.001 · Cited by 5
Pharmacogenetics and Pharmacogenomics
Voora, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800681-8.00016-5 · Cited by 5
Linking interpersonal differences in gut microbiota composition and drug biotransformation activityPreprint
Mastrorilli, E., Herd, P., Rey, F. E., Goodman, A. L., & Zimmermann, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.21.700809 · Cited by 5
“Although genes encoding drug-metabolizing enzymes can serve as biomarkers to predict community activity 4,7,25,26 , these analyses suggest that for many drugs, microbiome metabolic activity will not be readily predicted by the abundance of a single gene.”
Pathobionts in the microbiome: Drivers of disease and targets for treatment
Bharathi, S., Rajan, Y. A. P. A. S., Prakash, S., Immanuel, G., & Ramasubburayan, R. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.108268 · Cited by 7
Modulating drug response through the gut microbiome: pathways to precision therapy
Kumar, N., Das, J., Vanangamudi, M., Mojgani, N., Islam, A., Sridhar, S. B., Sharma, H., Kumar, S., Panigrahy, U. P., Mantry, S., et al. (2026) · Archives of Microbiology · doi:10.1007/s00203-025-04688-3 · Cited by 5
Habtemariam, S. (2026) · BioTech · doi:10.3390/biotech15020043 · Cited by 7
“Haiser et al. [69] showed that the gut bacterium E. lenta can inactivate the cardiac drug digoxin in a strain-dependent manner via a specific reductase enzyme system, leading to a reduction in bioavailability.”
Gut microbiota alters drug metabolism and therapeutic outcomes
Guo, F., Bai, Y., & Lei, X. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.06.001 · Cited by 7
Gut microbiota and cardiac arrhythmia: a pharmacokinetic scope
Nabeh, O. A. (2022) · The Egyptian Heart Journal · doi:10.1186/s43044-022-00325-2 · Cited by 7
“So, in patients with abundant Eggerthella lenta-cgr positive strains, antibiotics may be needed to increase serum digoxin level [37].”
BackgroundMingxiao, L. I., & Li, H. (2023) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(23)60493-5 · Cited by 6
Zhou, H. W., Yu, B., Sun, J., Chen, H., Liu, Z., Ge, L., & Chen, D. (2023) · Animal Biotechnology · doi:10.1080/10495398.2023.2248200 · Cited by 6
Long, A. R., Mortara, E. L., Mendoza, B. N., Fink, E. C., Sacco, F. X., Ciesla, M. J., & Stack, T. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110025 · Cited by 5
Wang, B., Ma, F., Du, X., Zhang, G., & Li, J. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1394302 · Cited by 4
Zhu, Y., Liu, Q., Alffenaar, J. C., Wang, S., Cao, J., Dong, S., Zhou, X., Li, X.-X., Li, X., Xiong, H., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3687 · Cited by 5
Gut Microbiota and Its Role in Metabolism of Common Drugs–A Short Review
Jamwal, R., & Goswami, S. K. (2015) · Pharmacology Toxicology and Biomedical Reports · doi:10.5530/ptb.1.3.2 · Cited by 4
“lenta strain is responsible for variation in the metabolism of digoxin by different people.(17) The same study revealed that arginine prevents the in vivo microbial metabolism of digoxin in mice and circulating microbial metabolite.”
BackgroundThe Tempo and Mode of Adaptation in a Complex Natural Population: the Microbiome
Garud, N. R. (2021) · mSystems · doi:10.1128/msystems.00779-21 · Cited by 5
“(2), metabolism of drugs (3), and evasion of antibiotics (4).”
BackgroundSchönborn, J. W., Stewart, F., Maas-Enriquez, K., Akhtar, I., Droste, A., Waschina, S., & Beller, M. (2021) · iScience · doi:10.1016/j.isci.2021.103216 · Cited by 6
“…including branched-chain amino acids (Lin et al., 2017; Liu et al., 2020), the metabolism of pharmaceuticals applied to the host (Clayton et al., 2009; Haiser et al., 2013), or the release of metabolites which affect signaling pathways of the host (Martin et al., 2019; Shin et al., 2011).”
BackgroundAge-dependent sexual dimorphism in the adult human gut microbiotaPreprint
Zhang, X., Zhong, H., Li, Y., Shi, Z., Zhang, Z., Zhou, X., Ren, H., Tang, S., Han, X., Lin, Y., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/646620 · Cited by 4
Psycho-pharmacomicrobiomics: a systematic review and meta-analysisPreprint
Minichino, A., Person, T., Fanshawe, J. B., Fusar‐Poli, P., McGuire, P. K., Burnet, P. W. J., & Lennox, B. (2023) · Research Square · doi:10.21203/rs.3.rs-2780131/v1 · Cited by 4
Dumitru, C. N., Dumitru, A. O., Goroftei, L., Niculet, E., Ignat, M. D., Baroiu, L., Nechita, A., & Balan, G. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18060651 · Cited by 4
“…azoreductases, bile salt hydrolases, sulphatases, nitroreductases) that can activate prodrugs, inactivate parent compounds, regenerate biliary-excreted metabolites through enterohepatic recirculation, and generate microbially derived metabolites with off-target pharmacological activity [1,10,11].”
How gut microbiota modulate anesthetic drug response and perioperative outcomes
Wang, D. (2026) · Drug Metabolism Reviews · doi:10.1080/03602532.2026.2630851 · Cited by 4
“…glycoside digoxin by Eggerthella lenta , thereby proving that gut microbes can materially change the pharmacologic fate of non-antibiotic drugs (Haiser et al. 2013, 2014). beyond direct chemical modification, the gut micro-biome exerts systemic control over host drug-metabolizing machinery and…”
Microbiome-driven PKs: redefining drug metabolism beyond host enzymes
Belančić, A., Fajkić, A., Lam, Y. W., Alić, L., Labriffe, M., Pilipović, K., Džidić-Krivić, A., Sy, H. Y., & Jankovic, S. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2631415 · Cited by 5
“[18]Factors in diet, such as polyphenols and oligofructose, can alter the abundance of A. muciniphila , a bacterium that helps potentiate PD-1/PD-1 ligand blockers which are used in cancer immunotherapy [113–115].”
InfluentialUnderstanding the Role of Gut Microbial Enzyme in CMD
Zhuo, Y., Yu, L., Jiang, C., & Wang, K. (2026) · Circulation Research · doi:10.1161/circresaha.125.326979 · Cited by 3
Mingolelli, G., Subedi, P., Bonitatibus, S., Johnson, J. J., & Henke, M. T. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117199 · Cited by 3
Translational Modeling of Gut Microbiome‐Mediated Drug Metabolism: A Case Example of Sulfasalazine
Cheng, L., Cai, J., Auster, A., Cho, S., Keir, M. E., Rhee, H. H., Kapili, B. J., Shalon, D., & Ning, M. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70246 · Cited by 4
Influence of Peanut Consumption on the Gut Microbiome: A Randomized Clinical Trial
Nguyen, S. M., Tran, T. D. C., Tran, T. M., Wang, C., Wu, J., Cai, Q., Ye, F., & Shu, X. (2024) · Nutrients · doi:10.3390/nu16193313 · Cited by 5
“…the gut microbiota regulates intestinal endocrine functions, providing a key source of energy biogenesis, biosynthesizing vitamins, modulating neurological signaling and neurotransmitters, metabolizing bile acids, reacting to or modifying specific drugs, and eliminating exogenous toxins [22–26].”
BackgroundEggerthella lenta down regulated flavone and flavonol biosynthesis promoted Kawasaki disease
Yeh, Y., Chen, K.-D., Huang, C., Tsai, J.-R., & Kuo, H. (2025) · Virulence · doi:10.1080/21505594.2025.2512401 · Cited by 3
“Eggerthella lenta has been reported to inhibit the Th17 master transcription factor, Rorγt) [7,8] and emerging evidence suggests that E. lenta is enriched in patients with multiple autoimmune diseases [9,10].”
Brar, A. S., Vemula, S. L., Yanamaladoddi, V. R., Sodhi, S. S., Hatwal, J., Sohal, A., & Batta, A. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i6.107386 · Cited by 7
Cardiovascular Health and Disease Prevention
Hanning, I. B., Lingbeck, J. M., & Ricke, S. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802189-7.00060-5 · Cited by 3
Intestinal microbiota – a new risk factor in cardiovascular diseases
Lyapina, I. N., Завырылина, П. Н., & Начева, Л. В. (2021) · Siberian medical review · doi:10.20333/25000136-2021-4-26-33 · Cited by 3
Understanding and role of gut microbiota on drug response and toxicity
Seshadri, S., Gajjar, D., Joshi, A., Bhatia, Z., & Kumar, S. (2024) · Journal of Toxicological Studies · doi:10.59400/jts.v2i1.1252 · Cited by 4
“Despite its identified function in the metabolism of digoxin, Eubacterium lenta is also present in individuals lacking the excretion of 20R-dihydrodigoxin [53].”
BackgroundAmir, S., Kumar, M., Kumar, V., & Mohanty, D. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.109679 · Cited by 4
Wu, L., Kensiski, A., Gavzy, S. J., Song, Y., Lwin, H. W., France, M., Kong, D., Li, L., Lakhan, R., Saxena, V., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02517-0 · Cited by 4
The Promise of Personalized Medicine
Stoll, M. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-79026-8_35 · Cited by 3
Geva‐Zatorsky, N., Elinav, E., & Pettersson, S. (2019) · BioEssays · doi:10.1002/bies.201900002 · Cited by 3
Role of Gut Microbiome in the Modulation of Environmental Toxicants and Therapeutic Agents
Hossain, A., Menezes, G. A., Al, M., & Ashankyty, I. (2016) · CRC Press eBooks · doi:10.1201/9781315371443-25 · Cited by 6
Gut Microbiome and Drug Metabolism
Ilina, E. N., Mayorova, E. M., Manolov, A. I., Korenkova, A. A., Bahmetjev, V. V., & Gorbunov, K. (2021) · Biomedical Chemistry Research and Methods · doi:10.18097/bmcrm00146 · Cited by 3
The meddling microbes midst our medicines
Viswanathan, V. K. (2013) · Gut Microbes · doi:10.4161/gmic.26250 · Cited by 5
“1).(2) Digoxin, a cardiac glycoside derived from the foxglove plant, is used for the treatment of heart conditions including atrial fibrillations and atrial flutter.”
Systems biology illuminates alternative metabolic niches in the human gut microbiomePreprint
Noecker, C. A., Sánchez, J. M., Bisanz, J. E., Escalante, V., Alexander, M., Trepka, K. R., Heinken, A., Liu, Y., Dodd, D., Thiele, I., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.19.508335 · Cited by 3
Self-citationGut Eggerthella lenta promotes the efficacy of resveratrol through reductive metabolismPreprint
Dong, Z., Yu, P., Zhou, H., Li, R., Sun, Q., Yang, Y., Gu, Y., & Jiang, W. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.10.584274 · Cited by 5
Huang, Y. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48552-4.00015-9 · Cited by 2
Biotransformation of antioxidant eriocitrin into characteristic metabolites by the gut microbiota
Zhang, H.-J., Yu, H., Fu, J., Keranmu, A., Zhang, Z., Xu, H., Hu, J.-C., Lu, J., Yang, X., Bu, M.-M., et al. (2023) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2023.2251123 · Cited by 2
Longwani, U., Sharma, A. K., Malwe, A. S., Jaiswal, S. K., & Sharma, V. K. (2025) · Gut Microbiome · doi:10.1017/gmb.2024.15 · Cited by 2
Human xenobiotic metabolism proteins have full-length and split homologs in the gut microbiome
Rendina, M. C., Turnbaugh, P. J., & Bradley, P. H. (2025) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkaf131 · Cited by 2
“1981), but the gene responsible was not identified until 2013 (Haiser et al .”
Self-citationGut bacteria and the host synergies promote resveratrol metabolism and induce tolerance in ALD mice
Zhang, S.-X., Hu, F.-F., Chen, H., Guo, J. S., Xiang, Z., Ding, X., Ye, M.-L., Ye, W.-L., Chen, J., Wang, X., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00766-y · Cited by 4
“Conversely, using inhibitors of these transport proteins can increase drug exposure and ef fi cacy in the body 32,33 .”
Microbiota–Drug Interaction and Its Influence on Drug Metabolism and Toxicity
Pal, R., Bhowmick, P., Mahanty, J., Halder, P., & Bhowmick, M. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-95-2104-3_3 · Cited by 3
Development of a gut microbiota model for the analysis of bacterial modifications of xenobiotics
Hager, N., Weyers, J.-L., Falk, L., Passon, M., Simon, M., Seel, W., Dorne, J. L. C. M., & Deppenmeier, U. (2026) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-026-13861-7 · Cited by 3
“…acid (Deloménie et al. 2001), as well as the modulation of drug efficacy and toxicity through reduction, hydrolysis, and competition with host metabolic pathways, as observed for digoxin (Haiser et al. 2013), irinotecan (Takasuna et al. 1996), and acetaminophen (Clay-ton et al. 2009).”
Hou, X., Guan, X., Qin, X., & Guo, H.-D. (2026) · Chinese Medicine · doi:10.1186/s13020-026-01336-w · Cited by 2
Jiang, L., Wang, B., Wang, W., Bai, B., Hou, Z., Ye, X., Jiang, Z., & Chen, S. (2026) · Food Research International · doi:10.1016/j.foodres.2026.118633 · Cited by 3
Wray, C., Castañeda-Monsalve, V., Engelmann, B., Rolle-Kampczyk, U. E., Schweiger, N., Gutsfeld, S., Ghosh, D., Kader, S., Tyler, C. R., Jehmlich, N., et al. (2026) · Toxicological Sciences · doi:10.1093/toxsci/kfag022 · Cited by 1
“More broadly, it supports the concept that microbiota mediate chemical toxicity (Haiser et al. 2013; Coryell et al. 2018; Catron et al. 2019; Brinkmann et al. 2020) and demonstrates that chemical–microbial interactions can manifest at the level of host neurobehavioral responses.”
Wang, P., Ding, L., Lang, Z., Zhang, Y., & Yu, Y. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl45081 · Cited by 3
Yang, P., & Gan, R. (2026) · iMetaOmics. · doi:10.1002/imo2.70097 · Cited by 2
Gajendiran, T. Y., Ganamurali, N., & Sabarathinam, S. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104683 · Cited by 2
sedeek, M., Ayoub, A., Hany, E., Bahaa, A., Bahr, A., Saher, O., & Ahmed, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1942291 · Cited by 2
Microbiome: pharmacokinetics, pharmacodynamics and drug/xenobiotic interactions
Ojezele, M. O. (2020) · African Journal of Clinical and Experimental Microbiology · doi:10.4314/ajcem.v21i2.1 · Cited by 2
Reveles, K. R., Young, E. H., Zeidan, A. R., & Dong, Q. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-815962-0.00017-2 · Cited by 2
Mukhtar, I., Anwar, H., Iftikhar, A., Hashem, H. E., Ali, Q., & Siddique, F. (2022) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-022-00618-x · Cited by 4
“However, drug-microbes interactions fared better as a complement to the efficacy and toxicity of drugs [13].”
BackgroundInteraction of Intestinal Microbiota with Medications
Liu, M., Xu, J., Jin, Q., & Li, Y. (2023) · Current Drug Metabolism · doi:10.2174/1389200224666230418104540 · Cited by 2
Gut Microbiota and Specific Response to Diet
Amamou, A., O’Mahony, C., Llopis-Grimalt, M. A., Cruzel, G., Caplice, N. M., Herisson, F. M., & Ghosh, S. (2024) · Endocrinology · doi:10.1007/978-3-031-35064-1_17 · Cited by 5
High-fidelity gut metagenome: A new insight of identification of fuctional probiotics
Wang, Y., Gao, P., Li, C., Lu, Y., Zhang, Y., Zhou, Y., & Kong, S. (2024) · Journal of Integrative Agriculture · doi:10.1016/j.jia.2024.05.011 · Cited by 4
Li, B., Kwok, L. Y., Wang, D., Li, L., Zhang, H., & Chen, Y. (2025) · Engineering · doi:10.1016/j.eng.2025.04.017 · Cited by 6
Gut Microbiota in Drug Metabolism: A New Frontier in Precision Medicine
Kaur, H. (2025) · INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT · doi:10.55041/ijsrem47264 · Cited by 2
Making Millennial Medicine More Meta
Turnbaugh, P. J. (2018) · mSystems · doi:10.1128/msystems.00154-17 · Cited by 5
Self-citationMa, Y., Liu, L., Chen, Q., & Ma, Y. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.650366 · Cited by 3
“A study on Eggerthella lenta strains in 2013 (Haiser et al., 2013) found that these strains carried a two-gene cardiac glycoside reductase (cgr) operon that was transcriptionally activated by digoxin (Doestzada et al., 2018), and thus resulted in the inactivation of the drug in cardiovascular…”
BackgroundAron‐Wisnewsky, J., Lefevre, C., & Bindels, L. B. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.01.004 · Cited by 4
Chakaroun, R., Massier, L., Musat, N., & Kovacs, P. L. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1756-4509 · Cited by 2
The microbiome and cardiovascular disease: Implications in Precision Medicine
Wang, Z., & Osborn, L. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00022-8 · Cited by 3
Molecular Evolution of Xenobiotic-Degrading Genes and Mobile Genetic Elements in Soil Bacteria
Khan, A., & Rao, T. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13320-6.00010-x · Cited by 4
Liu, Q., Xu, Y., Lv, X., Guo, C., Zhu, H., Liu, Y., & Wang, Y. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122891 · Cited by 2
Huang, W., & Zhang, W. (2020) · Springer eBooks · doi:10.1007/978-981-15-3895-7_10 · Cited by 2
Liou, C. S., Sirk, S. J., Diaz, C. A. C., Klein, A. P., Fischer, C. R., Higginbottom, S. K., Sonnenburg, J. L., & Sattely, E. S. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/626366 · Cited by 2
Gut Microbiome in Microbial Pathogenicity
Misra, P., & Singh, S. (2020) · Springer eBooks · doi:10.1007/978-981-15-8562-3_1 · Cited by 1
HIV infection and the gut microbiome
Khryanin, А. А., Pushkarev, E. V., & Bocharova, V. K. (2024) · HIV Infection and Immunosuppressive Disorders · doi:10.22328/2077-9828-2023-15-4-25-35 · Cited by 4
Capacity of the Human Gut Microbiome in Metabolism of Drugs and Its Interaction with CYP450 Enzymes
Shayeganpour, A. (2024) · Biochemistry · doi:10.5772/intechopen.112940 · Cited by 3
Exploring the human microbiome: Its role and impact on overall health and disease prevention
Alotaibi, F. M., Almazam, A. A., Alenezi, S. Z., Alanazi, M. H., Lamfon, N. A., Albalawi, A. E. A., Al-Nasser, N. S., & Altheyab, S. A. (2018) · International Journal of Health Sciences · doi:10.53730/ijhs.v2ns1.15085 · Cited by 1
Syama, K., Jothi, J. A. A., & Sivakumar, A. (2025) · Evolving Systems · doi:10.1007/s12530-025-09689-7 · Cited by 1
“For example, the gut bacterium Eggerthella lenta has a role in inactivating the cardiac drug clopidogrel , a commonly prescribed antiplatelet medication (Haiser et al 2013).”
Unexpected effects of antibiotics on microbiota-mediated drug metabolism in a fistulated dog model
Sousa, T., Yeung, C., Monsales, C. B. D., Sangfuang, N., Borde, A., Abrahamsson, B., & Basit, A. W. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107360 · Cited by 2
The Transmissibility of the Human Skin Virome: Potential Forensic Implications
Kim, M., Park, J. H., & Eom, Y. (2025) · MicrobiologyOpen · doi:10.1002/mbo3.70197 · Cited by 1
“…diversity of microbial communities varies depending on human health and various environmental factors (Turnbaugh et al. 2007; Kostic et al. 2012; Haiser et al. 2013), it is significantly less recognized that the diversity of the human virome persists within an individual (Virgin et al. 2009;…”
Host diets drive microbiome evolution and functional divergence
Nguyen, K. L., Xia, J. S., & Mei, W. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102068 · Cited by 1
“The susC/susD pair in the PUL of B. theta strain Bt-8736 enables the utilization of inulin, the homopolymer of β 2-1 fructose units, whereas the pair in the PUL of B. theta VPI-5482 , Bt-3731 , and Bt-7330 facilitates the utilization of levan, the homopolymer of β 2-6 fructose units.”
InfluentialGut microbiota‑metabolism axis in digestive tumors: Emerging targets for novel therapies (Review)
Yang, Z., Siyu, W. U., Yang, X., & Sui, B. (2026) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2026.13108 · Cited by 2
“…microbiota in the metabolism of xenobiotic compounds is detoxification and drug metabolism (117,118); for instance, Eggerthella lenta inactivates digoxin, a chemotherapeutic agent, and Enterococcus species can detoxify and mitigate the production of cisplatin‑induced reactive oxygen species (119).”
Gut-kidney axis: Dysbiosis and renal disease
Salvadori, M., & Rosso, G. (2026) · World Journal of Nephrology · doi:10.5527/wjn.v15.i1.115357 · Cited by 1
Peptidomics: A New Dimension in Microbiome Research
Hilpert, K. (2026) · Protein and Peptide Letters · doi:10.2174/0109298665436241260327111926 · Cited by 1
The Complex Interplay between Botanical Supplements and the Human Gut Microbiome
Ponte, A. T., Liu, A., Acquah, K. S., & Balunas, M. J. (2026) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5c01493 · Cited by 1
Gut microbial metabolism of Flutamide attenuates its therapeutic efficacy against prostate cancer
Li, S., Ding, H., Wang, J., Yuan, L., Zhou, Y., Xu, W., Yin, H., Ye, M., Sha, Y., Li, F., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2682803 · Cited by 1
“…can mediate the acetylation of 5-aminosalicylic acid, thereby reducing its therapeutic activity in inflammatory bowel disease, 21 inactivate digoxin in congestive heart failure via its reduction to dihydrodigoxin, 22,23 and cause hepatotoxicity from Brivudine by metabolizing it to bromovinyluracil.”
Recent advances and clinical relevance of microbiome dynamics in health and disease
Gavanji, S., Suhail, M., Bencúrová, E., Dandekar, T., & Othman, E. M. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2679197 · Cited by 4
Coyne, S., Ghergurovich, R., Sacco, F., Lombardi, F., Paar, K., Demartino, J., Kenfack, A., & Stack, T. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00661 · Cited by 1
Kadhim, A. S., Al-Karawi, A. S., & Atoom, A. M. (2026) · Comparative Immunology Reports · doi:10.1016/j.cirep.2026.200307 · Cited by 1
“…that contribute the efficacy of rituximab in RA [24,37]. there is another example, Eggerthella lenta, a gram-positive anaerobe enriched in some RA-associated microbiome profiles, encodes the cgr cytochrome gene cluster, which mediates the catabolism of a range of immunosuppressive xenobiotics [25].”
La medicina personalizada, la revolución genómica y el Sistema Nacional de Salud
Betancourt, J. D. L. C. H., & Serrano-Barrera, O. R. (2014) · Revista Cubana de Salud Pública · Cited by 1
Pharmacogenomics: Predicting Efficacy and Adverse Drug Reactions
Pirmohamed, M. (2014) · Cited by 1
Top Advances in Functional Genomics and Translational Biology for 2013
Pilbrow, A. P., Arora, P. K., Martinez‐Fernandez, A., Ali, Z. A., Arora, P. K., Chiao, Y. A., Desai, A. A., Gupta, R., Martinez‐Fernandez, A., Perez, M. V., et al. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000521 · Cited by 1
Jenkins, A., Cunningham, S., & O’Doherty, K. C. (2019) · Springer eBooks · doi:10.1007/978-3-030-25308-0_8 · Cited by 1
Pan-metagenomics: An overview of the human microbiome
Imchen, M., Vennapu, R. K., & Kumavath, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817076-2.00017-2 · Cited by 2
The Ageing Microbiome, Pharmaceutical Considerations, and Therapeutic Opportunities
Favaron, A., McCoubrey, L. E., Elbadawi, M., Basit, A. W., & Orlu, M. (2023) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-35811-1_8 · Cited by 2
Gut Microbiota and Specific Response to Diet
Amamou, A., O’Mahony, C., Llopis-Grimalt, M. A., Cluzel, G. L., Caplice, N. M., Herisson, F. M., & Ghosh, S. (2023) · Endocrinology · doi:10.1007/978-3-031-08115-6_17-2 · Cited by 1
The changes of gut microbiota and metabolites in different drug-induced liver injuries
Zhu, R., Gao, Y., Dong, J., Li, Z., & Ren, Z. (2023) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001778 · Cited by 1
Microbiota and the Cardiovascular System
Lorenzo, Ó., Lumpuy‐Castillo, J., Espadas, C., Parascinet, O., & Martínez-Albaladejo, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-65650-7_7 · Cited by 1
The right tool for the job: Chemical biology and microbiome science
Whidbey, C. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2024.12.004 · Cited by 2
Exploring the significance of gut microbiota in cardiovascular health
Akter, S., Choubey, M., Rahman, M. M., Arbee, S., Mohib, M. M., Tirumalasetty, M. B., Minhaz, N., Akhtar, A., Bismee, N. N., & Mohiuddin, M. S. (2025) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2025.2576444 · Cited by 3
“Factors like the kind and severity of the CVD, patient characteristics, risk assessments, efficacy, safety profiles, patient preferences, and adherence all have a significant impact on the choice of particular drugs (Table 1) [111].”
Neto, M. C., & O’Toole, P. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802304-4.00010-4 · Cited by 1
Microbes make metabolic mischief by targeting drugs
Lewis, K., & Strandwitz, P. (2019) · Nature · doi:10.1038/d41586-019-01851-x · Cited by 1
Metadata
- Authors
- Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J.
- Affiliations
- Harvard University (US)
- Corresponding author
- Turnbaugh, Peter J.
- Venue
- Science
- Published
- 2013-07-19
- Volume
- 341
- Issue
- 6143
- Pages
- 295-298
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3736355
- OpenAlex
- W2161185495
- Cited by
- 704
- References
- 25
- Citations by year
- 2026: 66 · 2025: 58 · 2024: 64 · 2023: 65 · 2022: 54 · 2021: 59 · 2020: 77 · 2019: 56 · 2018: 56 · 2017: 41 · 2016: 31 · 2015: 31 · 2014: 38 · 2013: 8
- FWCI
- 39.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (112991_1)
- National Institute of General Medical Sciences (P50GM068763)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034854)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Eggerthella lenta, digoxin, drug inactivation, gut microbiota, cytochrome P450, gnotobiotic mice, dietary protein, pharmacokinetics, cardiovascular drugs, human-microbe interactions
- MeSH terms
- Animals, Arginine, Cytochromes, Dietary Proteins, Digoxin, Feces, Germ-Free Life, Humans, Mice, Inbred Strains, Operon, Gene Expression Regulation, Bacterial, Actinobacteria, Gastrointestinal Tract, Mice, Metagenome, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.